natgillin/translations-raw huggingface dataset:
A method for treating atherosclerosis in a subject in need thereof comprising administering to the subject an antisense oligonucleotide, wherein the oligonucleotide modulates aberrant splicing of a human LMNA pre-mRNA, the oligonucleotide being composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′-exocyclic carbon of an adjacent subunit, containing about 12-40 bases; and having a targeting sequence comprising any one of SEQ ID NOs: 3-8, 10-18, and 20-34, wherein the antisense oligonucleotide is covalently attached to a cell-penetrating peptide and linker moiety of the formula -G-CPP, wherein G is the linker moiety and is selected from glycine, cysteine, proline, 6-aminohexanoic acid (Ahx), B-alanine (B), and Ahx-B, and CPP is the cell-penetrating peptide and is selected from SEQ ID NOS: 39-54. 
Protusmjerni oligonukleotid za smanjenje ekspresije abnormalno upletene LMNA mRNA, te oligonukleotid ima uglavnom nanabijenu okosnicu i sastavljen je od morfolino podjedinica i veza između podjedinica koje sadrže fosfor koje spajaju morfolino dušik jedne podjedinice na 5'-egzociklički ugljik susjedne podjedinice, koji sadržava 25-40 baza, te koji sadrži ciljajuću sekvencu koja sadrži bilo koju od SEQ ID NOs: 4, 5, 10, 11, 13, 14, i 16, pri čemu je protusmjerni oligonukleotid kovalentno vezan na peptid koji prodire u stanicu i skupine poveznice, pri čemu je skupina poveznice odabrana iz niza koji čine glicin, cistein, prolin, 6-aminoheksanoična kiselina (Ahx), B-alanin (B), i Ahx-B, te peptid koji prodire u stanicu je odabran od SEQ ID NOs: 39-54.
A pharmaceutical composition comprising the preparation of claim 1 . A method of treating cholestatic liver disease, non-alcoholic steato-hepatitis, alcoholic steato-hepatitis and/or arteriosclerosis by administering to a subject a pharmaceutical composition comprising a chemically pure, single-polymorphic, crystalline preparation of Nor-UDCA or of a pharmaceutically acceptable salt thereof containing a total amount of chemical impurities less than 2%, and at least 60% of the polymorph particles have a size <10 um. The method of claim 7, wherein the cholestatic liver disease is selected from the group consisting of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što raspodjela veličina čestica u farmaceutskom pripravku uključuje najmanje 60% čestice s veličinom < 10 µm. Polimorf u skladu s bilo kojim od patentnih zahtjeva 1 do 5, ili farmaceutski pripravak u skladu s patentnim zahtjevom 6 ili 7, naznačeni time što su namijenjeni upotrebi u liječenju kolestatske bolesti jetre, gdje se kolestatsku bolest jetre po mogućnosti bira iz skupine koju čine primarna bilijarna ciroza (PBC), primarni sklerozirajući kolangitis (PSC), autoimuni hepatitis (AIH) i preklapajući sindromi, uključujući sindrome koji se preklapaju s AIH.
Due to unpleasant ammonia emissions, workers on the impregnation systems do not want to use it. 
Zbog neugodnog isparavanja amonijaka, radnici na impregnacijskim sustavima ga ne žele upotrebljavati.
(a11) an antigen-binding site comprising an H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 105, 106, and 107 (H chain CDRs of Q499), respectively; 
(all) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 21 3 od SEQ ID NO: 105, 106 odnosno 107 (H-lanac CDR-područja od Q499);
TABLE 1 System Number of Hopping bits 
(21) Broj predmeta:
The weighted exercise apparatus according to claim 1, further comprising a strap secured to each handle and having a loop configured to receive a user's hand. 
Opterećena sprava za vježbanje u skladu s bilo kojim prethodnim zahtjevom, naznačena time da svaka ručka sadrži traku pričvršćenu na ručku i konfiguriranu da tvori kariku koja prima ruku korisnika.
In another aspect, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity. 
Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je namijenjena upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
The compound, the polymorphic form, or the pharmaceutical composition for use according to claim 10, wherein the condition is a skin disease or disorder, sepsis, dermatitis, osteoarthritis, cancer, inflammation, an autoimmune disease, inflammatory bowel disease, a complication from localized or total-body exposure to ionizing radiation, mucositis, acute or chronic organ failure, liver disease, pancreatitis, an eye disorder, a lung disease, or diabetes. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 10, naznačen time da stanje je kožna bolest ili poremećaj, sepsa, dermatitis, osteoartritis, rak, upala, autoimuna bolest, upalna bolest crijeva, komplikacija od lokaliziranog ili cjelokupnog izlaganja ionizirajućem zračenju, mukozitis, akutno ili kronično zatajenje organa, bolest jetre, pankreatitis, poremećaj oka, plućna bolest, 1li dijabetes.
The pharmaceutical composition of claim 8 or claim 9, wherein the pharmaceutical composition has a pH of from about 4 to about 6. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 4, gdje farmaceutska kompozicija ima pH od 4 do 6.
In one embodiment of the invention there is provided a process in which on the poultry being reared, the poultry are removed from the poultry shed and the poultry litter in the poultry shed is collected and delivered to a fuel storage area for subsequent thermal treatment to heat the poultry shed. 
Postupak sukladno bilo kojem od prethodnih Zahtjeva koji sadrži korak u kojem se, nakon uklanjanja komposta od korištenih gljiva iz prostora za uzgoj gljiva (3), kompost od korištenih gljiva dostavlja u prostor za skladištenje goriva (7) radi kasnijeg spaljivanja.
The process according to the above claims, characterized by reacting the compound of formula (II) with 1.05 equivalent of pyridinium tribromide in step iv). 
Postupak u skladu sa gornjim zahtjevima, naznačen time, da se provodi reakcija spoja formule (I) s 1.05 ekvivalenta piridinij tribromida u stupnju iv).
C1-6 alkyl optionally substituted by an -ORx group or a -Z-heterocyclyl group optionally substituted by an Ra group; 
-6 alkil po izboru supstituiran s -ORx grupom ili -Z-heterociklil grupu po izboru supstituiranu s Ra grupom;
A method of monitoring the efficacy of an anti-platelet therapy, the method comprising the steps of determining the level of at least one microRNA selected from the group consisting of miR-126, miR-197, miR-223, miR-24 and miR-21 in a plasma or serum sample obtained from an individual before the therapy, determining the level of at least one microRNA selected from the group consisting of miR-126, miR-197, miR-223, miR-24 and miR-21 in a plasma or serum sample obtained from an individual during or after the therapy, and comparing the determined levels in the individual before and during or after the therapy. 
Postupak praćenja učinkovitosti antitrombocitnog liječenja, postupak obuhvaća korake određivanja razine barem jedne mikroRNA odabrane iz skupine koju čine miR-126, miR-197, miR-223, miR-24 i miR-21, u uzorku plazme ili seruma dobivenog od pojedinca prije liječenja, before the therapy, određivanja razine barem jedne mikroRNA odabrane iz skupine koju čine miR-126, miR-197, miR-223, miR-24 i miR-21, u uzorku plazme ili seruma dobivenog od pojedinca za vrijeme ili nakon liječenja, i usporedbe dobivenih vrijednosti u pojedinca prije i za vrijeme ili nakon liječenja.
A pharmaceutical composition comprising an antibody of any one of claims 1 to 15 and/or a conjugate of claim 18 or 19, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo sukladno patentnom zahtjevu I i/ili konjugat sukladno patentnom zahtjevu 3 i farmaceutski prihvatljiv nosač.
Layer 1 consists of 33.3% w/w PLA, 33.3% w/w PBSA and 33.3% w/w PBAT; 
Višeslojna biorazgradiva folija prema zahtjevu 1, naznačena time da se sloj 1 sastoji iz 33,3% tež./tež. PLA, 33,3% tež./tež.
The compound of claim 7 wherein the compound is selected from the group consisting of and 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da je spoj odabran iz skupine koja se sastoji od [image] i [image]
The azo dye may be chosen from methyl violet, neutral red, para red, amaranth, carmoisine, allura red AC, tartrazine, orange G, ponceau 4R, methyl red, and murexide-ammonium purpurate. 
Upotreba u skladu s patentnim zahtjevom 6, naznačena time što se navedeno azo bojilo bira između metilnog ljubičastog, neutralnog crvenila, para crvenila, amaranta, azorubina, alura crvenila AC, tartrazina, narančastog G, košenilovog crvenila 4R, metilnog crvenila, te mureksid-amonijevog purpurata.
Addition of Buffer and Nicotine 
Dodavanje pufera i nikotina
A medicament comprising an effective amount of at least one compound as claimed in any of claims 1 to 55 and/or a pharmacologically acceptable salt thereof, pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients. 
Medikament, naznačen time što sadrži djelotvornu količinu najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 55, i/ili njegove farmakološki prihvatljive soli, farmaceutski prihvatljive pomoćne tvari i podloge, te, gdje je to prikladno, dodatne aditive i/ili druge aktivne sastojke.
The compound of formula (5) i.e. 
Spoj formule (5), tj.
providing a fibre pulp for a moulding process, the fibre pulp being contained in a pulp container, characterized in that the method comprises, 
priskrbljivanje pulpe od vlakana za postupak oblikovanja, pulpa od vlakana je sadržana u spremniku za pulpu (9), pri čemu metoda obuhvaća:
An object according to any one of the preceding claims, characterised in that the layer has a flexibility ranging from 1 to 9 mm measured according to ISO1520:1999. 
Objekt sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što sloj ima fleksibilnost u opsegu od 1 do 9 mm mjereno sukladno 1S01520:1999.
After week 8, dexamethasone will be added to the above regimens at an oral dose of 40mg daily on days 1, 8, 15 and 22 of a 4 week cycle. 
22. HuLuc63 za uporabu prema zahtjevu 21, naznačen time da se bortezomib daje na dane 1, 4, 8 1 11 nakon čega slijedi razdoblje od 10 dana mirovanja.
Dosage form for use according to embodiments 7 or 8, wherein the volume of the application fluid per nostril is within a range of about 200 µl to about 35 µl, preferably of about 200 µl to about 50 µl, more preferably of about 200 µl to about 100 µl. 
Oblik doziranja za uporabu prema zahtjevu 5 ili 6, naznačen time da volumen tekućine za primjenu po nosnici je u rasponu od 200 ul do 35 ul, poželjno od 200 ul do 50 ul, poželjnije od 200 ul do 100 ul.
A kit comprising a solid formulation according to any one of claims 1 to 16 and a package leaflet or user instruction including the information that said formulation is to be used for the prevention and/or treatment of congestive heart failure in a mammal, preferably in a dog, cat or rodent, in need of such prevention or treatment. 
Garnitura, naznačena time, da obuhvaća kruti pripravak prema bilo kojem od zahtjeva 1 do 16 i pakirani listić ili uputstvo za korisnika, koji sadrži informaciju da se kruti pripravak treba upotrebljavati za prevenciju i/ili liječenje kongestivnog srčanog zastoja kod sisavca, poželjno kod psa, mačke ili glodavca, kojima treba takva prevencija ili liječenje.
The composition for use according to claim 13, which further comprises bisphosphonates or the pharmaceutically acceptable salts thereof. 
Kombinirani pripravak prema zahtjevu 8, naznačen time što je pripravak u obliku prilagođenom za intravensku primjenu.
Membrane cassette (11) according to claim 3, wherein an upper membrane separator and a lower membrane separator are coupled by coupling portions (23, 24) formed on wall surfaces opposed to each other of water collecting cases (14) of the membrane separators. 
Membranska kaseta (11) prema zahtjevu 3, naznačena time da su gornji membranski separator i donji membranski separator povezani sa spojnim dijelovima (23, 24) formiranim na površinama stjenki međusobno nasuprot kučišta za prikupljanje vode (14) membranskih separatora.
The method of claim 1, wherein the solid form is anhydrous. The method of claim 1, wherein the solid form exhibits a mass increase of less than approximately 0.5% when subjected to an increase in relative humidity from approximately 0% to approximately 95% relative humidity. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što čvrsti oblik pokazuje povećanje mase manje od otprilike 0,5% kada se podvrgne povećanju relativne vlažnosti od otprilike 0% do otprilike 95% relativne vlažnosti.
the 5' end of the modified oligonucleotide; or 
’ kraju modificiranog oligonukleotida; ili
The compound of claim 11 or 12 or a pharmaceutically acceptable salt thereof wherein R1 is 4-trifluoromethylpyrazol-1-yl or 4-trifluoromethylimidazol-1-yl. 
Spoj u skladu s patentnim zahtjevom 11 ili 12, ili njegova farmaceutski prihvatljiva sol, naznačen time što je R1 4-trifluormetilpirazol-1-il ili 4-trifluormetilimidazol-1-il.
reducing the above compound of formula XIa to obtain a compound of formula Va in the form of diastereoisomeric mixture (S,R+R,R) and, if desired, separating the compound of formula Va (S,R+R,R) into the single diastereomer Va (S,R) and the single diastereomer Va (R,R). 
X) redukciju navednog spoja formule Xla, da bi se dobio spoj formule Va prema zahtjevu 1 u obliku dijasteroizomerne smjese (S, R+R, R) i, po želji, odvajanje smjese formule Va (S, R+R, R) na zaseban 15 dijasteromer Va (S, R) i zaseban dijasteromer Va (R, R).
The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. 
Farmaceutski pripravci tako mogu biti u oblicima suspenzija, otopina ili emulzija u ulju ili vodenim otapalima, te mogu sadržavati sredstva z formuliranje poput sredstva za suspenziranje, stabiliziranje i/ili dispergiranje.
A composition according to claim 1 or 2, wherein Y is NH. 
Pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da Y je NH.
FIG. 4 shows a sheet metal strip on termination of the incision stage, 
prikazuje limenu metalnu traku na završetku faze urezivanja, slika 5
a monoclonal antibody comprising a light chain variable domain containing residues 44-54, 70-76 and 109-117 of SEQ ID NO:6; 
monoklonalnog antitijela koje sadrži varijabilno područje lakog lanca koje sadrži ostatke 44-54, 70-76 i 109-117 od SEQ ID br. 6;
The medicinal aerosol suspension of claims 1 to 7, the pharmaceutical composition of claims 8 and 9 or the pharmaceutical suspension formulation of claim 10 for use in the treatment of inflammation and preferably for the treatment of asthma and allergic rhinitis. 
Medicinska aerosolna suspenzija u skladu s patentnim zahtjevima 1 do 7, farmaceutski pripravak u skladu s patentnim zahtjevima 8 i 9 ili farmaceutska suspenzijska formulacija u skladu s patentnim zahtjevom 10, naznačeni time što su namijenjeni upotrebi u liječenju upale i po mogućnosti u liječenju astme i alergijskog rinitisa.
The method of claim 1, wherein the pharmaceutical composition is isotonic with body fluid, buffered at physiological pH of 7.2 to 8.5, and ready to use for intravenous infusion. 
Farmaceutski pripravak koji sadrži 4mg/ml ibuprofena u vodenoj otopini, tris-pufer i arginin, molarni omjer arginina prema ibuprofenu veći je ili jednak 1,000625:1, taj pripravak je izotoničan s tjelesnom tekućinom, puferiran na fiziološki pH od 7,2 do 8,5, i spreman za uporabu kao intravenska infuzija.
A medicament comprising glatiramer acetate for use in treating a patient who is suffering from a relapsing form of multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament is to be administered in a regimen of three subcutaneous injections of a 40mg dose of glatiramer acetate every seven days with at least one day between each subcutaneous injection and wherein the pharmaceutical composition further comprises mannitol. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu u liječenju čovjeka kao pacijenta koji pati od relapsirajućeg oblika multiple skleroze, naznačen time, da se daje u režimu od tri supkutane injekcije dozom od po 40 mg glatiramer acetata svakog tjedna s barem jednim danom između svake supkutane injekcije i u čemu farmaceutski sastav nadalje sadrži manitol i ima pH u području od 5,5 do 7,0.
provided that when M is Li, the compound of Formula IIb is not a compound of Formula VII wherein R17 is OH; and 
time formirajući spoj Formule IIb gdje je R'* OH; pod uvjetom kada je M Li, spoj Formule IIb nije spoj Formule VII
A process according to any preceding claim, wherein the refrigeration system is suitable for use with chlorodifluoromethane (HFC-22) and the refrigerant composition is subsituted for HFC-22 in the system. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da je rashladna tvar pogodna za upotrebu sa klorodifluorometanom (HFC-22) 1 rashladna tvar zamjenjuje tvar HFC-22 u sustavu.
Other suitable pharmaceutical agents, in addition to anti-obesity agents, that can be used in combination with the compounds of the present invention include agents useful in the treatment of concomitant disorders. 
Slijedeće prikladno farmaceutsko sredstvo, kao dodatak sredstvima protiv debljine, koje se može kombinirati sa spojevima prikazanog izuma uključuje sredstva korisna u liječenju popratnih poremećaja.
A compound according to claim 4 in which the inflammatory disorder is selected from the group consisting of asthma, adult respiratory distress, syndrome, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, diabetes, inflammatory bowel disease, osteoporosis, psoriasis, graft vs. host rejection, atherosclerosis, pain, and arthritis including rheumatoid arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, gouty arthritis and osteoarthritis. 
Uporaba spoja prema zahtjevu 10, naznačena time što se radi o upalnom poremećaju iz skupine koja obuhvaća astmu, sindrom respiratornog distresa kod odraslih, kroničnu opstruktivneu plućnu bolest, kroničnu plućnu inflamatornu bolest, dijabetes, upalnu bolest crijeva, osteoporozu, psorijazu, odbacivanja transplantanta, aterosklerozu, bol i artritis, uključujući reumatoidni artritis, psorijatični artritis, traumatski artritis, rubella artritis, giht i osteoartritis
Collect the filtrate and concentrate to give brown solid. 
Filtrat je sakupljen i koncentriran pri čemu se dobiva smeđa krutina.
wherein the device is configured to read at least one form comprising: 
Postupak prema zahtjevu 18, naznačen time da kamera sadrži barem jednu leću.
An acoustic and/or thermal insulating product based on mineral wool sized using the sizing composition as claimed in claim 1 . 
Zvučni i / ili toplinski izolacijski proizvod na bazi mineralne vune dobiven postupkom sukladno jednom od zahtjeva 1 do 10.
A is optionally substituted aryl or optionally substituted heteroaryl; 
A je izborno supstituiran aril ili izborno supstituiran heteroaril;
i)) a first segment comprising a nucleotide sequence that is complementary to a target sequence in the target DNA; 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna sekvenci u ciljanoj DNK, i
The composition of claim 1, comprising: baclofen or a pharmaceutically acceptable salt thereof, sorbitol or a pharmaceutically acceptable salt thereof, and naltrexone or a pharmaceutically acceptable salt thereof as active ingredients in a relative weight ratio of about 8.6/300/1, 
- < baklofen, sorbitol i naltrekson kao aktivne sastojke u relativnom omjeru masa oko 8,6/300/1, acetatni pufer pH vrijednosti oko 5,5, oko 0,18 % w/v metil parahidroksibenzoata i 0,02 % w/v propil parahidroksibenzoata, i otprilike 0,04 % w/v izoamil acetata.
TACI extracellular domain or fragment thereof which binds BlyS; and 
(i) < izvanstanična domena TACI ili njezin fragment koji veže BLyS; i
reacting a compound of formula (I) with an intermediate of formula (11) by nucleophilic substitution of the fluoride at the ring position of a compound of formula (I) (herein referred to as Step 9) wherein 
reakciju spoja s formulom (I) s međuproduktom s formulom (11) nukleofilnom supstitucijom fluorida na položaju prstena spoja s formulom (I) (ovdje se naziva korak 9) pri čemu
water in an amount of about 2% to about 10% by weight of the composition and a carrier medium comprising 
(ii) vodu u količini od oko 2 masena % do oko 15 masenih % od sastava;
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a pH that is set at X±0.05 wherein X has a value of from 7.15 to 7.20, with the proviso that the pH is set at greater than 7.10, wherein the cell culture is a continuous culture maintained at a density of 1.4x106 to 2.8x106 cells/ml. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što supernatant kulture stanica ima koncentraciju otopljenog CO2 od 1 do 10%, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml.
The control system (1) of claim 7 or 8, wherein said coupling pin (32) is provided with threaded axial hole (33). 
Kontrolni sustav (1) prema zahtjevu 7 1li 8, naznačen time da je spojmi klin (32) opremljen aksijalnim otvorom s navojem (33).
The product of claim 1, further comprising one or more whiteners selected from the group consisting of milk, cream, non dairy creamer, soymilk, rice milk, and coconut milk. 
Proizvod u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži jedno ili više bjelila, koja se bira iz skupine koju čine mijeko, slatko vrhnje, umjetno vrhnje nemliječnog podrijetla, sojino mijeko, rižino mijeko, te kokosovo mijeko.
Surprisingly it has been found that compounds of formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; 
NN CH, naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) spoj fenpropidin.
In accordance with the convention used at the encoder CO, which is the same at the decoder DO, an even value of the sum of the coefficients in the sublist SEm1 means that the sign of the first non-zero coefficient in the modified list Em1 is positive, while an odd value of the sum of the coefficients in the sublist SEm1 means that the sign of the first non-zero coefficient in the modified list Em1 is negative. 
- predznak prvog nenultog koeficijenta je pozitivan kada navedeni zbroj koeficijenata ima parnu vrijednost, dok je predznak prvog nenultog koeficijenta negativan kada navedeni zbroj koeficijenata ima neparnu vrijednost.
Administration of a compound according to the invention will be greatly aided by the manufacture of pharmaceutical compositions. 
Primjenu spoja prema ovom izumu uvelike će olakšati proizvodnja farmaceutskih pripravaka.
The method, the aerosol, or the composition of aspect 45, wherein the buffer in the composition has a concentration of 10 to 100 mM, preferably 10 to 50 mM, such as 10 mM or 20 mM, in particular 10 mM. 
Pripravak prema zahtjevu 8, naznačen time što pufer u pripravku ima koncentraciju od 10 do 100 mM, poželjno 10 do 50 mM, kao što je 10 mM ili 20 mM, naročito 10 mM.
RD2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl; 
RD2 je odabran iz skupine koja sadrži vodik, halogen, po izboru supstituiran C1-6 alkil, po izboru supstituiran C2-6alkenil i po izboru supstituiran C2-6 alkinil;